Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Myriad is a healthcare company focused on molecular diagnostics and therapeutic product development. It operates three segments: Research, Molecular Diagnostics, and Pharmaceutical Development. The Molecular Diagnostics segment is the primary revenue driver, offering genetic testing for disease risk and drug response.
Key Financial Metrics
| Metric | Q3 2008 | Q3 2007 |
|---|---|---|
| Total Revenue | $73.7 million | $48.3 million |
| Net Income (Loss) | $14.5 million | ($8.0 million) |
| Operating Income (Loss) | $13.3 million | ($11.6 million) |
| Earnings Per Share (Diluted) | $0.30 | ($0.18) |
| Cash and Cash Equivalents | $230.2 million | $107.2 million |
| Total Investments (Marketable Securities) | $212.4 million | N/A |
| Net Cash Used in Operating Activities | ($4.4 million) | ($12.7 million) |
| Accumulated Deficit | ($190.1 million) | N/A |
Liquidity: As of September 30, 2008, the company held $442.6 million in cash, cash equivalents, and marketable investment securities. The company reported no long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 53% year-over-year, driven primarily by a 52% increase in molecular diagnostic revenue ($70.0 million vs. $46.1 million) due to higher testing volumes and expanded sales efforts.
- Profitability Turnaround: The company shifted from a net loss of $8.0 million in Q3 2007 to a net income of $14.5 million in Q3 2008. This was driven by revenue growth and a significant reduction in R&D expenses.
- R&D Expense Reduction: Research and development expenses decreased 34% to $17.1 million, primarily due to the discontinuation of the drug candidate Flurizan, which saved approximately $11.1 million.
- SG&A Increase: Selling, general, and administrative expenses rose 26% to $33.4 million, attributed to increased sales/marketing costs, higher bad debt expense ($1.9 million increase), and share-based compensation.
- Investment Impairment: The company recorded a $2.0 million "other than temporary impairment" loss on Lehman Brothers Holdings, Inc. bonds due to the issuer's bankruptcy filing.
Guidance, Outlook, and Risks
- Corporate Separation: On October 20, 2008, the Board authorized the separation of the Research and Pharmaceutical Development businesses from the Molecular Diagnostics business. The transaction is anticipated to be a pro-rata, tax-free dividend distribution, with a Form 10 registration expected in Q2 2009.
- Investment Portfolio Risks: The company holds $1.9 million in Level 3 assets (auction rate securities) with limited liquidity due to failed auctions. Additionally, there are estimated unrealized losses of $6.6 million in the investment portfolio, primarily related to financial institution bonds, which management currently deems temporary.
- Drug Development Uncertainty: Future cash flows depend heavily on the success of clinical trials for candidates such as Azixa (brain tumors) and Vivecon (AIDS). Management notes that projecting costs and timelines for these programs is difficult.
- Capital Resources: Management believes existing capital resources are sufficient to fund operations for at least the next two years, though they may seek additional financing if market conditions are favorable.
Investor Verification Checklist
- Separation Timeline: Verify the progress of the planned spin-off of the research/pharma division and the allocation of assets/liabilities between the two new entities.
- Investment Valuation: Monitor the status of the $1.9 million in auction rate securities and the $6.6 million in unrealized losses to ensure they remain classified as temporary.
- Clinical Trial Results: Track the Phase 2 results for Azixa and Phase 2a results for Vivecon, as these are critical for future pharmaceutical revenue potential.
- Bad Debt Trends: Review the allowance for doubtful accounts, which increased by $4.4 million in the quarter, to assess the collectability of receivables from the growing diagnostic business.
- Regulatory Approvals: Monitor FDA interactions regarding the company's drug candidates and molecular diagnostic products.